
|Videos|August 30, 2022
Selecting an Effective Treatment Approach Informed by Recent mCSPC Research
Author(s)Marc Matrana, MD
Clinical insights concerning the selection of effective treatment approaches for patients with mCSPC with comments on the study design and results of the TITAN study.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5







































